"An FDA approval enables oncologists to use oxaliplatin (Eloxatin,
Sanofi-Synthelabo) with fluorouracil/leucovorin (5FU/LV) as first-line treatment
for advanced colorectal cancer. The combination, known as FOLFOX, was approved
in August 2002 for second-line treatment of patients with recurrent or
progressing disease after treatment with 5FU/LV."

http://www.hemonctoday.com/200402/frameset.asp?article=oxal.asp

Eric

[Non-text portions of this message have been removed]